Clinical Research Directory

Inclusion Criteria * Histologically confirmed prostate adenocarcinoma within 365 days of registration. * Clinical stages T1a-T2c N0 M0 (AJCC Criteria 6th Ed). For any suspicious pelvic lymph node \> 1.5cm (as exhibited on pelvic imaging), biopsy of the lymph node is suggested. * Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason score must be in the range 2-7. Biopsy with \> 6 cores is strongly recommended. (The highest Gleason Score in any core reported on the pathology report will be used for determining inclusion.) * PSA values \<20 ng/ml within 90 days prior to registration, and done either prior to prostate biopsy, or at least 21 days after prostate biopsy. * Zubrod (ECOG) status 0-1 documented within 90 days of registration. * Androgen deprivation is at the discretion of the treating radiation oncologist. * Subjects must give IRB-approved study-specific informed consent. Subjects must complete all required tests within the specified time frames. * Subjects must be at least 18 years old. * Members of all races and ethnic groups are eligible for this trial. Exclusion Criteria * Clinical stages T3 or greater (AJCC Criteria 6th Ed). * PSA of 20 ng/ml or greater. * Gleason score 8 or higher. * Evidence of distant metastasis. (Determined by CT scan, MRI, and/or bone scan prior to the simulation appointment; imaging results from UPHS will supercede results from similar scans from an outside facility.) * Evidence of lymph node involvement. * Previous prostate cancer surgery to include: prostatectomy, hyperthermia, and cryosurgery. * Previous pelvic radiation for prostate cancer. * Active rectal diverticulitis, Crohn's disease, or ulcerative colitis. * Prior systemic chemotherapy for prostate cancer. * History of proximal urethral stricture requiring dilatation.